2-Chloro-1-(4-trifluoromethoxy-benzyl)-1H-benzoimidazole | 875004-94-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-Chloro-1-(4-trifluoromethoxy-benzyl)-1H-benzoimidazole
• 英文别名: 2-chloro-1-[[4-(trifluoromethoxy)phenyl]methyl]benzimidazole
• CAS: 875004-94-7
• 化学式: C₁₅H₁₀ClF₃N₂O
• 分子量: 326.705
• InChiKey: GXMUNPALUFPCPG-UHFFFAOYSA-N

物化性质

• 沸点：
  423.7±55.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-Chloro-1-(4-trifluoromethoxy-benzyl)-1H-benzoimidazole 在 三乙胺 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 10.5h， 生成 9-(4-(trifluoromethoxy)benzyl)-3,9-dihydro-2H-benzo[d]imidazo[1,2-a]imidazole
  参考文献：
  名称：

  Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi

  摘要：

  A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 μM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.

  DOI：

  10.1016/j.ejmech.2014.07.038
• 作为产物：
  描述：

  1-(4-trifluoromethoxybenzyl)-1,3-dihydro-benzoimidazol-2-one 在 三氯氧磷 作用下， 生成 2-Chloro-1-(4-trifluoromethoxy-benzyl)-1H-benzoimidazole
  参考文献：
  名称：

  Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists

  摘要：

  Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.086

文献信息

• MEDICINAL USE OF RECEPTOR LIGANDS
  申请人：Receveur Jean-Marie

  公开号：US20090062317A1

  公开（公告）日：2009-03-05

  Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5 membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or —OCH 3 ; X is ═CH— or ═N—; L, is —CH 2 — or —CH 2 CH 2 —; L 2 is a bond, —CH 2 — or —CO—; R2 is H or C, —C 3 alkyl, or —N(R 2 ) L, —is selected from specific cyclic amino linker radicals as defined in the specification; ring A is selected from specific N-containing heterocyclic rings as defined in the specification.

  式(I)的化合物是黑素浓集激素-1受体(MCH-1R)的配体，可用于治疗对黑素浓集激素(MCH)活性调节敏感的疾病，例如进食障碍和肥胖是危险因素的疾病（式(I)）：其中环B选自规定的特定取代苯基或苯并5元杂环；R附着在环B的环碳上，表示氢，F，Cl或—OCH3；X为═CH—或═N—；L为—CH2—或—CH2CH2—；L2为键，—CH2—或—CO—；R2为H或C，—C3烷基，或—N(R2)L，—选自规定的特定环状氨基连接基团。环A选自规定的特定含氮杂环。
• Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists
  作者：Pradip K. Sasmal、Sanjita Sasmal、P. Tirumala Rao、B. Venkatesham、M. Roshaiah、Chandrasekhar Abbineni、Ish Khanna、Vikram P. Jadhav、J. Suresh、Rashmi Talwar、Syed Muzeeb、Jean-Marie Receveur、Thomas M. Frimurer、Øystein Rist、Lisbeth Elster、Thomas Högberg

  DOI：10.1016/j.bmcl.2010.07.086

  日期：2010.9

  Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. (c) 2010 Elsevier Ltd. All rights reserved.
• [EN] MEDICINAL USE OF RECEPTOR LIGANDS<br/>[FR] UTILISATION MEDICALE DE LIGANDS RECEPTEURS
  申请人：7TM PHARMA AS

  公开号：WO2006010446A2

  公开（公告）日：2006-02-02

  Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1 R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5­membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or -OCH3; X is =CH- or =N-; L, is -CH2- or -CH2CH2- ; L2 is a bond, -CH2- or -CO-; R2 is H or C,-C3 alkyl, or -N(R2) L,- is selected from specific cyclic amino linker radicals as defined in the specification; ring A is selected from specific N- containing heterocyclic rings as defined in the specification.
• Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi
  作者：Sangmi Oh、Sungbum Kim、Sunju Kong、Gyongseon Yang、Nakyung Lee、Dawoon Han、Junghyun Goo、Jair L. Siqueira-Neto、Lucio H. Freitas-Junior、Rita Song

  DOI：10.1016/j.ejmech.2014.07.038

  日期：2014.9

  A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 μM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.